Search the Newsreel

Heritage Investors Management Corp Sells 9,615 Shares of ConocoPhillips $COP

Heritage Investors Management Corp reduced its stake in ConocoPhillips (NYSE:COP) by 4.8% in the second quarter, selling 9,615 shares, though still holding 189,417 shares worth approximately $19.7 million. ConocoPhillips reported strong Q2 results with EPS of $3.24 and revenue up 32.4% year over year, …

Caitong International Asset Management Co. Ltd Raises Stock Position in ConocoPhillips $COP

Caitong International Asset Management Co. Ltd significantly increased its stake in ConocoPhillips (NYSE:COP) by 3,112.4% in the second quarter, now owning 17,604 shares valued at $1.83 million. ConocoPhillips reported strong Q2 earnings with EPS beating estimates and revenue up 32.4% year-over-year, driven by record …

Top Pyrophyte Acquisition Corp. II (PAII) Competitors 2026

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

Sutro Biopharma, Inc. (NASDAQ:STRO) Just Reported And Analysts Have Been Lifting Their Price Targets

Theravance Biopharma Deal Faces Investor Probe

Halper Sadeh LLC is investigating the proposed acquisition of Theravance Biopharma (NASDAQ: TBPH) by Zymeworks Inc. for $17 per share in cash plus a contingent value right. The investigation aims to determine if Theravance shareholders are receiving a fair price and if the company's …

Technical Reactions to AVBP Trends in Macro Strategies

This article provides a technical analysis of Arrivent Biopharma Inc. (NASDAQ: AVBP) trends, highlighting neutral near and mid-term readings but a potentially strong long-term positive bias. It details institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The …

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. The investigation focuses on whether Theravance's board failed to secure the best possible price, conducted a fair sales process, …

Wedge Capital Management L L P NC Buys Shares of 128,845 Theravance Biopharma, Inc. $TBPH

Wedge Capital Management L L P NC recently acquired 128,845 shares of Theravance Biopharma (NASDAQ:TBPH) worth approximately $2.19 million, now owning about 0.25% of the company. Institutional investors hold 99.10% of TBPH, despite the company reporting an adjusted loss and missing revenue expectations in …

Connect Biopharma (NASDAQ:CNTB) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen has upgraded Connect Biopharma (NASDAQ:CNTB) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with an average price target of $7.43. The company recently reported a quarterly loss of $0.27 per share, outperforming expectations, …

Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold

Wall Street Zen has upgraded Vor Biopharma (NASDAQ:VOR) from a "sell" to a "hold" rating. Despite this, the overall analyst consensus for Vor Biopharma remains a "Moderate Buy" with an average price target of $43.38, though the company's stock trades significantly below its 52-week …

Arbutus Biopharma (NASDAQ:ABUS) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded Arbutus Biopharma (NASDAQ:ABUS) from a "buy" to a "hold" rating, though Weiss Ratings simultaneously upgraded it from "sell" to "hold." The biopharmaceutical company holds a consensus "Moderate Buy" rating and a $5.00 price target. Despite missing quarterly EPS estimates by …

Vor Biopharma (VOR) sees Frazier Life Sciences entities report under 5% ownership

Frazier Life Sciences-affiliated funds have filed an amended Schedule 13G indicating beneficial ownership of less than 5% of Vor Biopharma Inc. common stock. Frazier Life Sciences Public Fund, L.P. holds 4.2% of the class, while Frazier Life Sciences XII, L.P. holds 0.5%, and Frazier …

Theravance Biopharma (TBPH): Newtyn discloses 6.7% holdings in amended 13G/A

Newtyn Management, LLC has disclosed a 6.7% beneficial ownership in Theravance Biopharma (TBPH) through an amended Schedule 13G filing. While Newtyn TE Partners, LP, a part of Newtyn Management, has reduced its holdings to below the 5% reporting threshold, Newtyn Management itself remains above …

Ikarian Capital (CNTB) discloses 6.9% Connect Biopharma holding on Schedule 13G/A

Ikarian Capital, LLC and Neil Shahrestani have disclosed a 6.9% beneficial ownership in Connect Biopharma Holdings Limited Ordinary Shares through a Schedule 13G/A filing. This ownership amounts to 4,338,534 shares, based on 62,974,309 Ordinary Shares outstanding as of July 31, 2026. The filing indicates …

Insider Selling: Cue Biopharma (NASDAQ:CUE) CEO Sells 18,258 Shares

Cue Biopharma CEO Shao-Lee Lin sold 18,258 shares of the company's stock for over $522,000 to cover tax withholding obligations from vested equity awards. This sale reduced her ownership by 2.52%, following a previous sale of 40,000 shares for $1.08 million. The company recently …

Cue Biopharma CEO Lin sells shares worth $1.6 million

Cue Biopharma CEO Lin Shao-Lee sold shares worth $1.6 million, primarily to cover tax obligations from vested restricted stock units, not as discretionary sales. Concurrently, Mr. Lin acquired 109,179 shares from vested performance stock units. The company has also appointed a new Chief Medical …

Insider plans 58,258-share stock sale (NASDAQ: CUE) under Rule 144

An insider of Cue Biopharma (NASDAQ: CUE) has filed a Rule 144 notice to sell up to 58,258 shares of common stock. These shares originated from restricted stock units that vested on August 1, 2026. The sale is planned to occur in two tranches …

Cue Biopharma (NASDAQ:CUE) Posts Quarterly Earnings Results, Misses Estimates By $22.45 EPS

Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells 4,000 Shares of Stock

SOPHiA GENETICS (NASDAQ:SOPH) insider Zhenyu Xu sold 4,000 shares of the company's stock on August 13th for $30,080, reducing his position by 0.68%. This sale was part of a pre-arranged Rule 10b5-1 trading plan, and Xu has made several other sales since early July. …

Helix BioPharma Reshapes Board to Align with Oncology Growth Strategy

Helix Biopharma Corp. Announces Board Composition Changes

Vor Biopharma (VOR) sees Venrock-led group report 9.99% ownership stake

A Venrock-led group, including Venrock Healthcare Capital and individuals Nimish Shah and Bong Koh, has reported a beneficial ownership stake of 9.99% in Vor Biopharma Inc. (VOR). This stake comprises 5,676,370 shares of common stock, including Pre-Funded Warrants, as of June 30, 2026. A …

Sutro Biopharma (STRO): Perceptive Advisors reports 7.9% beneficial stake

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 7.9% of Sutro Biopharma's common stock, totaling 1,304,846 shares. This ownership is based on 16,572,171 shares outstanding as of August 7, 2026. The reporting persons have …

Lyell Immunopharma (LYEL): Foresite funds and Tananbaum report 2.7% ownership

Foresite Capital-affiliated funds and James B. Tananbaum have reported a beneficial ownership of 653,328 shares of Lyell Immunopharma (LYEL) common stock, representing 2.7% of the class. This disclosure was made in an updated SCHEDULE 13G/A SEC filing. The ownership is primarily held by Foresite …

RA Capital boosts Karyopharm (KPTI) stake to 9.99% beneficial ownership cap

RA Capital Management, L.P. and its affiliated reporting persons have reported a 9.99% beneficial ownership stake in Karyopharm Therapeutics Inc. (KPTI) as of June 30, 2026. This stake, totaling 2,302,504 shares, is held through RA Capital Healthcare Fund, L.P., and is capped at 9.99% …

ConocoPhillips stock outperforms competitors on strong trading day

ConocoPhillips (COP) stock advanced by 1.81% to $126.78 on a strong trading day, outperforming competitors and the broader market indices like the S&P 500 and Dow Jones Industrial Average, which both saw declines. Despite the market downturn, ConocoPhillips closed 6.69% below its 52-week high.

GT Biopharma (NASDAQ: GTBP) wins approval for reverse split and share plan changes

GT Biopharma shareholders approved a reverse stock split, ranging from 1-for-10 to 1-for-30, and a reduction in authorized shares to 25,000,000 common and 1,500,000 preferred shares. They also approved a 3,500,000-share increase to the 2022 Omnibus Incentive Plan and an evergreen provision for automatic …

ABUS|Arbutus Biopharma Corp|Price:4.710|Chg%:+0.130

Pyrophyte Acquisition Corp. II Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Sutro Biopharma (STRO): Point72 group reports 1.4% stake in 13G/A

Point72 Asset Management, along with Point72 Capital Advisors, Inc. and Steven A. Cohen, has filed an amended SCHEDULE 13G/A, reporting a 1.4% beneficial ownership stake in Sutro Biopharma (STRO). This represents 237,827 shares of common stock as of June 30, 2026, with shared voting …

ConocoPhillips reaches $5 billion divestiture target early after completing $1.7 billion noncore asset sale

ConocoPhillips has exceeded its $5 billion divestiture target ahead of schedule, driven by a recent $1.7 billion sale of noncore Lower 48 assets. This strategic move aligns with a broader industry trend among U.S. shale producers to streamline portfolios, focus on higher-return assets, and …

ConocoPhillips awards Noble jackup rig a North Sea P&A contract

ConocoPhillips has awarded Noble Interceptor a 670-day plug-and-abandonment (P&A) contract in the Greater Ekofisk Area offshore Norway, starting in Q3 2027. This contract, valued for its long duration, strengthens Noble's presence in the North Sea P&A market and adds to a series of recent …